ANN ARBOR, Mich., – December 9, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that its research and development (“R&D”) team has expanded their research focus far beyond the spider silk proteins in the Company’s Monster Silk® and Dragon SilkTM products. These new protein designs have the potential to create new materials and open additional markets for the Company’s recombinant silk technologies.
With the additional research personal hired this year, the Company has been able to expand its R&D into new and exciting arenas. The lab team has recently identified innovative native protein sequences from an exotic species that has demonstrated performance beyond the capabilities of the Company’s current transgenics.
The DNA encoding, from specific portions of this species’ proteins, have been synthesized and are already in the Company’s labs. These proteins are believed to be responsible for the amazing performance that the native materials exhibit.
The R&D team employed its new “mix and match” assembly system, which allows for accelerated development and performance experimentation, to design the new DNA domains to integrate with the Company’s existing DNA constructs. This approach allows the Company to produce a fiber containing a blend of current technologies with new DNA constructs to form an array of new tailored materials.
“I am very excited by the possibilities these new DNA constructs can offer. By incorporating these new designs with our proven ‘mix and match’ assembly system, we are opening new doors and a vast array of end material properties.” said Chief Scientist, Trevor Kane, Ph.D. “I applaud my team for the willingness and determination to continually expand the cutting edge of transgenic spider silk research.”
The Company believes that these new DNA constructs should enhance future transgenic silkworm capabilities, as the isolated DNA, in these new proteins, exhibit higher performance than the Company’s original baseline transgenic spider silk proteins.
While the Company’s R&D team continues to push the boundaries of scientific possibilities, the Company will continue to advance the commercialization of its current suite of technologies, which have different target markets. In fact, the Company’s production arm, Prodigy Textiles, is preparing to make its first commercial delivery of enhanced fibers in the first quarter of 2020. In support of this phase, the Company’s COO will be travelling to Prodigy Textiles to oversee this exciting evolutionary step in its journey to commercialize and deliver spider silk on a global scale.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495